Magellan Health to explore sale after pressure from prominent hedge fund

After coming under pressure from activist hedge fund Starboard Value, U.S. health plan and pharmacy benefit manager Magellan Health will explore selling itself, according to Reuters.

Advertisement

Magellan is looking for ways to boost its value. Since April 2018, its shares have dropped nearly 40 percent.

In response, the company intends to start a multiyear improvement plan to shore up finances.

People familiar with the plan say Magellan is considering being acquired by other companies.

Starboard has a 9.8 percent stake in the company.

Read the full report here.

 

More articles on pharmacy:
FTC settles with Teva over ‘pay-for-delay’ deals
Top 10 fatal or harmful prescribing errors
Civica Rx will start as middleman for drugmakers, hospitals, Bloomberg says

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

The Performance Gap Your Pharmacy Training Metrics Can’t See

Monday, August 10
12:00 PM - 1:00 PM CDT

Presenters: Michael Alexander, AudirieDr. Tina Moen, PharmD, Colibri Healthcare

Advertisement

Next Up in Pharmacy

Advertisement

Comments are closed.